Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars

Colorectal cancer (CRC) is a leading cause of tumor-related morbidity and mortality worldwide, with mortality most often attributable to metastatic disease. Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, has a significant role in the treatment of metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosen, Lee S., Jacobs, Ira A., Burkes, Ronald L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610666/
https://www.ncbi.nlm.nih.gov/pubmed/28801849
http://dx.doi.org/10.1007/s11523-017-0518-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610666/
https://www.ncbi.nlm.nih.gov/pubmed/28801849
http://dx.doi.org/10.1007/s11523-017-0518-1

Ejemplares similares